Mouse models of prostate cancer: picking the best model for the question

被引:87
作者
Grabowska, Magdalena M. [1 ]
DeGraff, David J. [1 ]
Yu, Xiuping [1 ]
Jin, Ren Jie [1 ]
Chen, Zhenbang [2 ]
Borowsky, Alexander D. [3 ]
Matusik, Robert J. [1 ]
机构
[1] Vanderbilt Univ, Nashville, TN 37235 USA
[2] Meharry Med Coll, Nashville, TN 37208 USA
[3] Univ Calif Davis, Davis, CA 95616 USA
关键词
Mouse models; Prostate cancer; TRAMP; LADY; PTEN; Myc; SMALL-CELL CARCINOMA; ANDROGEN RECEPTOR; INTRAEPITHELIAL NEOPLASIA; GENE-EXPRESSION; PTEN LOSS; MOLECULAR CHARACTERIZATION; MALIGNANT-TRANSFORMATION; NEUROENDOCRINE CARCINOMA; CONDITIONAL EXPRESSION; HISTOLOGICAL VARIANTS;
D O I
10.1007/s10555-013-9487-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
When the National Institutes of Health Mouse Models of Human Cancer Consortium initiated the Prostate Steering Committee 15 years ago, there were no genetically engineered mouse (GEM) models of prostate cancer (PCa). Today, a PubMed search for "prostate cancer mouse model" yields 3,200 publications and this list continues to grow. The first generation of GEM utilized the newly discovered and characterized probasin promoter driving viral oncogenes such as Simian virus 40 large T antigen to yield the LADY and TRAMP models. As the PCa research field has matured, the second generation of models has incorporated the single and multiple molecular changes observed in human disease, such as loss of PTEN and overexpression of Myc. Application of these models has revealed that mice are particularly resistant to developing invasive PCa, and once they achieve invasive disease, the PCa rarely resembles human disease. Nevertheless, these models and their application have provided vital information on human PCa progression. The aim of this review is to provide a brief primer on mouse and human prostate histology and pathology, provide descriptions of mouse models, as well as attempt to answer the age old question: Which GEM model of PCa is the best for my research question?.
引用
收藏
页码:377 / 397
页数:21
相关论文
共 163 条
[1]  
Abate-Shen C, 2003, CANCER RES, V63, P3886
[2]   Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia [J].
Abdulkadir, SA ;
Magee, JA ;
Peters, TJ ;
Kaleem, Z ;
Naughton, CK ;
Humphrey, PA ;
Milbrandt, J .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (05) :1495-1503
[3]   Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition [J].
Acevedo, Victor D. ;
Gangula, Rama D. ;
Freeman, Kevin W. ;
Li, Rile ;
Zhang, Youngyou ;
Wang, Fen ;
Ayala, Gustavo E. ;
Peterson, Leif E. ;
Ittmann, Michael ;
Spencer, David M. .
CANCER CELL, 2007, 12 (06) :559-571
[4]   The role of murine models of prostate cancer in drug target discovery and validation [J].
Ahmad, Imran ;
Sansom, Owen J. ;
Leung, Hing Y. .
EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (08) :879-888
[5]   SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation [J].
Ahuja, D ;
Sáenz-Robles, MT ;
Pipas, JM .
ONCOGENE, 2005, 24 (52) :7729-7745
[6]   Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer [J].
Aitchison, Alan A. ;
Veerakumarasivam, Abhi ;
Vias, Maria ;
Kumar, Rajeev ;
Hamdy, Freddie C. ;
Neal, David E. ;
Milis, Ian G. .
PROSTATE, 2008, 68 (06) :661-674
[7]   Replacing the mouse androgen receptor with human alleles demonstrates glutamine tract length-dependent effects on physiology and tumorigenesis in mice [J].
Albertelli, Megan A. ;
Scheller, Arno ;
Brogley, Michele ;
Robins, Diane M. .
MOLECULAR ENDOCRINOLOGY, 2006, 20 (06) :1248-1260
[8]  
[Anonymous], 1995, Lancet, V346, P265
[9]  
[Anonymous], SEER STAT FACT SHEET
[10]  
Ayala G, 2003, CLIN CANCER RES, V9, P4792